Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization

• Status: Not yet recruiting
• Trial end date: 2030-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeshi Morimoto
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Patients with chronic coronary syndromes with ≧50% diameter stenosis in one or more major coronary vessels/major branches on coronary CT or coronary angiography but not eligible for coronary revascularization

• Patients for whom consent can be obtained

Exclusion Criteria:

• Patients with history of acute coronary syndromes (ACS)

• Patients with history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)

• Patients with left main trunk stenosis (≥50%)

• Patients for whom aspirin administration is mandatory

• Patients undergoing antithrombotic therapy other than aspirin

• Patients with atrial fibrillation

• Patients with history of stroke within six months

• Patients scheduled for major surgical procedures that will require aspirin discontinuation

• Patients with contraindication of aspirin

• Patients expected to have a prognosis of 1 year or less due to comorbidities

• Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization

• Patients who are judged by attending physicians to be inappropriate to participate in this study